curasan AG receives €1.48 million research grant
The Israeli working group has synthesised and patented a peptide matrix which can be used to significantly speed up the process of bone regeneration. However, the protein matrix needs to be combined with a suitable carrier material to achieve its full potential.
As a partner of BGU, curasan AG will now develop and produce a bioceramic optimised for this purpose. This new material should retain the characteristics required for the growth of bone matter that were provided by the previously available purely inorganic, absorbable materials.
“The funding that has been allocated will help us to develop a generation of products with an active mechanism”, explains Dr. Fabian Peters, Head of Research and Development of Biomaterials at curasan AG.
The aim of the research partnership is to create a special bioactive product which, when combined with organic substances, will support the body’s own healing processes and enable optimal bone regeneration. curasan AG will have the rights of sale.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.